The takeaway from these studies: Obesity is a chronic condition and without ongoing treatment (whether medication, surgery, or intensive behavioral support), biology will try to pull weight back up
The increment of insulin secretion in response to GLP-1 or GIP infusion during the hyperglycemic clamp study indicates the -cell incretin sensitivity [9-11]
The 2023 case report noted the occurrence of drug-induced lupus in an individual on semaglutide
Schmidt did, clinicians may struggle to navigate risks for novel uses amid so many unknowns
Danones GLP-1 strategy: summary Danone targets GLP-1 users with whey-rich yoghurt supporting muscle health Microbiome focused medical nutrition aims to rebalance gut impacted by treatment Kate Farms offers high protein plant based shakes supporting satiety and muscle health Consumer and medical approaches expand opportunities as GLP-1 demand grows Launch timing and markets depend on regulation alignment and patient needs As the early signs of GLP-1-driven disruption emerge in the food sector, more manufacturers are exploring weight management-friendly innovation
Current evidence suggests that dulaglutide and extended-release formulations generally demonstrate lower nausea rates compared to twice-daily exenatide or higher-dose semaglutide and liraglutide
